title: Randomized study of the crush technique versus provisional side-branch stenting in true coronary bifurcations: the CACTUS (Coronary Bifurcations: Application of the Crushing Technique Using Sirolimus-Eluting Stents) Study.
abstract: BACKGROUND
  Sirolimus-eluting stents have been reported to be effective in the treatment of coronary bifurcations. Still, it has not been fully clarified which strategy would provide the best results with true bifurcation lesions.
  
  
  RESULTS
  The CACTUS trial (Coronary bifurcations: Application of the Crushing Technique Using Sirolimus-eluting stents) is a prospective, randomized, multicenter study comparing 2 different techniques of stenting, with mandatory final kissing-balloon inflation, in true bifurcations: (1) elective "crush" stenting and (2) stenting of only the main branch, with provisional side-branch T-stenting. From August 2004 to June 2007, 350 patients were enrolled in 12 European centers. The primary angiographic end point was the in-segment restenosis rate, and the primary clinical end point was the occurrence of major adverse cardiac events (cardiac death, myocardial infarction, or target-vessel revascularization) at 6 months. At 6 months, angiographic restenosis rates were not different between the crush group (4.6% and 13.2% in the main branch and side branch, respectively) and the provisional stenting group (6.7% and 14.7% in the main branch and side branch, respectively; P=NS). Additional stenting on the side branch in the provisional stenting group was required in 31% of lesions. Rates of major adverse cardiac events were also similar in the 2 groups (15.8% in the crush group versus 15% in the provisional stenting group, P=NS).
  
  
  CONCLUSIONS
  In most bifurcations with a significant stenosis in both branches, a provisional strategy of stenting the main branch only is effective, with the need to implant a second stent on the side branch occurring in approximately one third of cases. The implantation of 2 stents does not appear to be associated with a higher incidence of adverse events at 6 months.
authors.affiliation: Interventional Cardiology Unit, San Raffaele Scientific Institute, Milan, Italy. info@emocolumbus.it
authors.forename: Antonio
authors.initials: A
authors.lastname: Colombo
authors.forename: Ezio
authors.initials: E
authors.lastname: Bramucci
authors.forename: Salvatore
authors.initials: S
authors.lastname: Saccà
authors.forename: Roberto
authors.initials: R
authors.lastname: Violini
authors.forename: Corrado
authors.initials: C
authors.lastname: Lettieri
authors.forename: Roberto
authors.initials: R
authors.lastname: Zanini
authors.forename: Imad
authors.initials: I
authors.lastname: Sheiban
authors.forename: Leonardo
authors.initials: L
authors.lastname: Paloscia
authors.forename: Eberhard
authors.initials: E
authors.lastname: Grube
authors.forename: Joachim
authors.initials: J
authors.lastname: Schofer
authors.forename: Leonardo
authors.initials: L
authors.lastname: Bolognese
authors.forename: Mario
authors.initials: M
authors.lastname: Orlandi
authors.forename: Giampaolo
authors.initials: G
authors.lastname: Niccoli
authors.forename: Azeem
authors.initials: A
authors.lastname: Latib
authors.forename: Flavio
authors.initials: F
authors.lastname: Airoldi
mesh_terms: D000368:Aged; D015906:Angioplasty, Balloon, Coronary / Q000379:methods*; D017023:Coronary Angiography; D003324:Coronary Artery Disease / Q000000981:diagnostic imaging / Q000628:therapy*; D023903:Coronary Restenosis / Q000517:prevention & control*; D003331:Coronary Vessels; D054855:Drug-Eluting Stents; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage; D008297:Male; D008875:Middle Aged; D020123:Sirolimus / Q000008:administration & dosage; D016896:Treatment Outcome
chemical_list: D007166:Immunosuppressive Agents; D020123:Sirolimus